Misoprostol in Office Hysteroscopy and Endometrial Biopsy

• Status: Withdrawn
• Trial end date: 2020-03-25
• Target enrollment: 0
• Participant gender: Female

Summary

We hypothesize that use of vaginal misoprostol will help in reducing the pain scores when used prior to concurrent office hysteroscopy and endometrial biopsy in a particular subgroup of women who are anticipated to require cervical dilatation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of South Florida
• Treatments: Misoprostol

Criteria

Inclusion Criteria:

All consecutive female patients aged 18-70 years presenting to the Center for successive OH and EMB with the ability to provide written informed consent and meets at least one of the criteria mentioned below:

• Previous cesarean section

• Nulliparous

• Postmenopausal

• Previous loop electrosurgical excision procedure (LEEP) or cone biopsy

• Previous myomectomy

Exclusion Criteria:

Premenopausal multiparous women with no prior surgeries performed on the uterus.

• Patients unable to provide informed consent

• Patients visiting the fibroid and endometriosis center with abnormal uterine bleeding, infertility or for preoperative evaluation; however, OH and EMB is not required for their evaluation based on their providers' clinical judgment.

• Patients with genital tract lesions.